GH Research (NASDAQ:GHRS) Upgraded to "Strong-Buy" at Cantor Fitzgerald

Cantor Fitzgerald upgraded shares of GH Research (NASDAQ:GHRS - Free Report) to a strong-buy rating in a research note published on Tuesday, May 13th,Zacks.com reports. Cantor Fitzgerald also issued estimates for GH Research's FY2025 earnings at ($0.84) EPS.

Several other equities research analysts have also issued reports on GHRS. Royal Bank of Canada initiated coverage on shares of GH Research in a research note on Friday, March 7th. They issued an "outperform" rating and a $31.00 price target on the stock. Guggenheim decreased their price objective on GH Research from $32.00 to $29.00 and set a "buy" rating for the company in a report on Friday, May 9th. HC Wainwright reiterated a "buy" rating and set a $40.00 target price on shares of GH Research in a report on Friday, May 9th. Finally, Stifel Nicolaus increased their price target on GH Research from $18.00 to $32.00 and gave the company a "buy" rating in a research report on Thursday, February 27th. Six investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of "Buy" and a consensus target price of $30.43.

GH Research Trading Up 9.8%

Shares of GHRS stock traded up $1.15 on Tuesday, hitting $12.85. 256,447 shares of the stock were exchanged, compared to its average volume of 177,395. The firm has a market capitalization of $668.51 million, a P/E ratio of -16.39 and a beta of 0.86. GH Research has a fifty-two week low of $6.00 and a fifty-two week high of $20.50. The business has a 50-day moving average of $10.28 and a 200 day moving average of $9.97.

GH Research (NASDAQ:GHRS - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The company reported ($0.19) earnings per share for the quarter, topping analysts' consensus estimates of ($0.61) by $0.42. As a group, research analysts forecast that GH Research will post -0.8 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in GHRS. Geode Capital Management LLC boosted its position in GH Research by 4.5% during the fourth quarter. Geode Capital Management LLC now owns 72,513 shares of the company's stock worth $508,000 after purchasing an additional 3,092 shares during the period. AdvisorShares Investments LLC boosted its holdings in shares of GH Research by 15.4% during the 4th quarter. AdvisorShares Investments LLC now owns 36,011 shares of the company's stock worth $252,000 after buying an additional 4,806 shares during the period. BNP Paribas Financial Markets acquired a new position in GH Research in the 4th quarter valued at about $44,000. Northern Trust Corp raised its holdings in GH Research by 26.8% in the 4th quarter. Northern Trust Corp now owns 40,834 shares of the company's stock valued at $286,000 after acquiring an additional 8,641 shares during the period. Finally, Palumbo Wealth Management LLC acquired a new stake in GH Research during the first quarter worth approximately $142,000. 56.90% of the stock is currently owned by institutional investors.

GH Research Company Profile

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).